Akt Inhibitor (Akti-1/2), Akt1/2 kinase inhibitor (ab142088)
Key features and details
- Potent isozyme selective Akt1/2 kinase inhibitor
- CAS Number: 612847-09-3
- Purity: > 99%
- Soluble in DMSO to 10 mM
- Form / State: Solid
- Source: Synthetic
Overview
-
Product name
Akt Inhibitor (Akti-1/2), Akt1/2 kinase inhibitor -
Description
Potent isozyme selective Akt1/2 kinase inhibitor -
Alternative names
- Akti-1/2
-
Biological description
Potent isozyme selective Akt1/2 kinase inhibitor. (IC50 values are 58, 210 nM and 2.12 mM for Akt1, Akt2, and Akt3, respectively). No inhibition against pleckstrin homology (PH) domain-lacking Akts, PKA, PKC and SGK.
-
Purity
> 99% -
CAS Number
612847-09-3 -
Chemical structure
Properties
-
Chemical name
3-[1-[[4-(7-Phenyl-3H-imidazo[4,5-g]quinoxalin-6-yl)phenyl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one -
Molecular weight
551.65 -
Molecular formula
C34H29N7O -
PubChem identifier
10196499 -
Storage instructions
Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
Solubility overview
Soluble in DMSO to 10 mM -
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
C1CN(CCC1N2C3=CC=CC=C3NC2=O)CC4=CC=C(C=C4)C5=NC6=CC7=C(C=C6N=C5C8=CC=CC=C8)N=CN7 -
Source
Synthetic
-
Research areas
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
References (18)
ab142088 has been referenced in 18 publications.
- Xu P et al. Hypoxia-mediated YTHDF2 overexpression promotes lung squamous cell carcinoma progression by activation of the mTOR/AKT axis. Cancer Cell Int 22:13 (2022). PubMed: 34996459
- Mao XQ et al. RNA-seq and ATAC-seq analyses of multilineage differentiating stress enduring cells: Comparison with dermal fibroblasts. Cell Biol Int 46:1480-1494 (2022). PubMed: 35673985
- Tang W et al. Suppression of CX3CL1 by miR-497-5p inhibits cell growth and invasion through inactivating the ERK/AKT pathway in NSCLC cells. Cell Cycle 21:1697-1709 (2022). PubMed: 35485293
- Afsar SY et al. Sphingosine-1-phosphate-lyase deficiency affects glucose metabolism in a way that abets oncogenesis. Mol Oncol 16:3642-3653 (2022). PubMed: 35973936
- Kataoka S et al. The costimulatory activity of Tim-3 requires Akt and MAPK signaling and its recruitment to the immune synapse. Sci Signal 14:N/A (2021). PubMed: 34131021